The ubiquitin system: pathogenesis of human diseases and drug targeting.
暂无分享,去创建一个
[1] Christopher A Ross,et al. Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.
[2] J. Lowe,et al. Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein , 2000, Neuroscience Letters.
[3] D. Bowtell,et al. The Cbl protooncoprotein stimulates CSF‐1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation , 1999, The EMBO journal.
[4] S. Elledge,et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.
[5] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[6] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[7] V. Buchman,et al. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.
[8] J. Adams. Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.
[9] S. Fang,et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[10] P. Ratcliffe,et al. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. , 2003, Seminars in cancer biology.
[11] Isao Nishimura,et al. Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.
[12] T. Chase,et al. Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.
[13] R. Kaufman. Orchestrating the unfolded protein response in health and disease. , 2002, The Journal of clinical investigation.
[14] J. Hodgson,et al. Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme* , 1996, The Journal of Biological Chemistry.
[15] Michele Pagano,et al. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. , 2003, Seminars in cancer biology.
[16] T. Rapoport,et al. The Pathway of Us11-Dependent Degradation of Mhc Class I Heavy Chains Involves a Ubiquitin-Conjugated Intermediate , 1999, The Journal of cell biology.
[17] A. Dabrowska,et al. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. , 2000, Anticancer research.
[18] B. Bonavida,et al. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. , 1999, Biochemical and biophysical research communications.
[19] Takayuki Harada,et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice , 1999, Nature Genetics.
[20] R. Klausner,et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[22] A. Goldberg,et al. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Goldberg,et al. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? , 2001, Current opinion in clinical nutrition and metabolic care.
[24] R. Bowser,et al. The septin CDCrel-1 binds syntaxin and inhibits exocytosis , 1999, Nature Neuroscience.
[25] R. Twombly. First proteasome inhibitor approved for multiple myeloma. , 2003, Journal of the National Cancer Institute.
[26] E. Hol,et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation , 2002, The Journal of cell biology.
[27] T. Hunter,et al. Recognition and Ubiquitination of Notch by Itch, a Hect-type E3 Ubiquitin Ligase* , 2000, The Journal of Biological Chemistry.
[28] I. Dikic,et al. Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.
[29] D. Green. Death and NF-κB in T Cell Activation: Life at the Edge , 2003 .
[30] R. Ueda,et al. Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. , 1995, Oncogene.
[31] S. Jentsch,et al. A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly , 1999, Cell.
[32] M. Gstaiger,et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. , 1999, Genes & development.
[33] M. Lalande,et al. UBE3A/E6-AP mutations cause Angelman syndrome , 1996, Nature Genetics.
[34] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.
[35] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[36] Y. Yarden,et al. The role of ubiquitylation in signaling by growth factors: implications to cancer. , 2003, Seminars in cancer biology.
[37] M. Ivan,et al. The von Hippel-Lindau tumor suppressor protein. , 2001, Current opinion in genetics & development.
[38] F. Gergely,et al. BRCA1-independent ubiquitination of FANCD2. , 2003, Molecular cell.
[39] G. Courtois,et al. Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation , 1998, Cell.
[40] M. Mann,et al. Identification of the receptor component of the IκBα–ubiquitin ligase , 1998, Nature.
[41] M. Scheffner,et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.
[42] A. Spada,et al. Polyglutamines Placed into Context , 2003, Neuron.
[43] S. Ganesan,et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.
[44] M. Gurney,et al. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[45] T. Ouchi,et al. Autoubiquitination of the BRCA1·BARD1 RING Ubiquitin Ligase* , 2002, The Journal of Biological Chemistry.
[46] T. Dawson,et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[47] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[48] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[49] T. Hunter,et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.
[50] Thomas Ludwig,et al. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. , 2002, Current opinion in genetics & development.
[51] C. Pickart,et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] P. Kloetzel,et al. Ubiquitin and proteasomes: Antigen processing by the proteasome , 2001, Nature Reviews Molecular Cell Biology.
[53] V. Denenberg,et al. Altered Activity, Social Behavior, and Spatial Memory in Mice Lacking the NTAN1p Amidase and the Asparagine Branch of the N-End Rule Pathway , 2000, Molecular and Cellular Biology.
[54] W. Krek,et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL , 2003, Nature Cell Biology.
[55] Stefan Imreh,et al. Inhibition of antigen processing by the internal repeat region of the EpsteinBarr virus nuclear antigen-1 , 1995, Nature.
[56] W. Birchmeier,et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex , 2002, Nature Cell Biology.
[57] A. Haeringen,et al. Angelman syndrome: a review of clinical and genetic aspects , 1999, Clinical Neurology and Neurosurgery.
[58] David Pearce,et al. Phosphorylation of Nedd4‐2 by Sgk1 regulates epithelial Na+ channel cell surface expression , 2001, The EMBO journal.
[59] M. Fortini,et al. Genetic analysis of the role of the drosophila fat facets gene in the ubiquitin pathway. , 1999, Developmental genetics.
[60] S. Emr,et al. Ubiquitin-Dependent Sorting into the Multivesicular Body Pathway Requires the Function of a Conserved Endosomal Protein Sorting Complex, ESCRT-I , 2001, Cell.
[61] G. Courtois,et al. NF-κB Defects in Humans: The NEMO/Incontinentia Pigmenti Connection , 2000, Science's STKE.
[62] N. Hattori,et al. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.
[63] A. D’Andrea,et al. Regulation of the Fanconi anemia pathway by monoubiquitination. , 2003, Seminars in cancer biology.
[64] P. Lockhart,et al. Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.
[65] A. Weissman,et al. RING Finger Proteins Mediators of Ubiquitin Ligase Activity , 2000, Cell.
[66] M. Masucci,et al. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies. , 2003, Seminars in cancer biology.
[67] Paul Polakis,et al. Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.
[68] N. Copeland,et al. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice , 1998, Nature Genetics.
[69] G. Viglietto,et al. Understanding p27kip1 Deregulation in Cancer: Downregulation or Mislocalizaiton? , 2002, Cell cycle.
[70] R. Kopito,et al. Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.
[71] G. Courtois,et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination , 2003, Nature.
[72] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[73] J. Hoeijmakers,et al. Inactivation of the HR6B Ubiquitin-Conjugating DNA Repair Enzyme in Mice Causes Male Sterility Associated with Chromatin Modification , 1996, Cell.
[74] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[75] M. Kitagawa,et al. An F‐box protein, FWD1, mediates ubiquitin‐dependent proteolysis of β‐catenin , 1999, The EMBO journal.
[76] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[77] A. Matouschek,et al. Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.
[78] A. Goldberg,et al. Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.
[79] M. Scheffner,et al. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[80] K. Fischbeck,et al. Triplet repeat expansion in neuromuscular disease , 2000, Muscle and Nerve.
[81] Haruchika Masuda,et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.
[82] A. Goldberg,et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] Hans Clevers,et al. Caught up in a Wnt storm: Wnt signaling in cancer. , 2003, Biochimica et biophysica acta.
[84] R. Kopito,et al. Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.
[85] D. Rotin. Regulation of the epithelial sodium channel (ENaC) by accessory proteins , 2000, Current opinion in nephrology and hypertension.
[86] J. Mestan,et al. Skp2 is oncogenic and overexpressed in human cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[87] P. Elliott,et al. Proteasome inhibition: A novel mechanism to combat asthma. , 1999, The Journal of allergy and clinical immunology.
[88] A. Smahi,et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. , 2002, Human molecular genetics.
[89] A. Goldberg,et al. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.
[90] A. Fischer,et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling , 2001, Nature Genetics.
[91] A. Ashworth,et al. Identification of the familial cylindromatosis tumour-suppressor gene , 2000, Nature Genetics.
[92] R. Baker,et al. Characterization of the ubiquitin-specific protease activity of the mouse/human Unp/Unph oncoprotein. , 2000, Biochimica et biophysica acta.
[93] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[94] A. Varshavsky,et al. An Essential Role of N-Terminal Arginylation in Cardiovascular Development , 2002, Science.
[95] A. Ciechanover,et al. Inhibition of NF‐κB cellular function via specific targeting of the IκB‐ubiquitin ligase , 1997 .
[96] C. Ross,et al. Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.
[97] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[98] H. Moch,et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.
[99] M. Gurney,et al. SEL‐10 interacts with presenilin 1, facilitates its ubiquitination, and alters A‐beta peptide production , 2002, Journal of neurochemistry.
[100] A. Goldberg,et al. Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.
[101] F. Tortella,et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. , 2000, Stroke.
[102] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[103] R. Tanzi,et al. Endoproteolytic Cleavage and Proteasomal Degradation of Presenilin 2 in Transfected Cells* , 1997, The Journal of Biological Chemistry.
[104] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[105] P. Thomas,et al. Activity and Regulation of the Centrosome-associated Proteasome* , 2000, The Journal of Biological Chemistry.
[106] P. Kloetzel,et al. Expression of Alzheimer’s Disease-associated Presenilin-1 Is Controlled by Proteolytic Degradation and Complex Formation* , 1998, The Journal of Biological Chemistry.
[107] G. Yancopoulos,et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo , 2001, Nature Cell Biology.
[108] G. Roomans. Pharmacological treatment of the ion transport defect in cystic fibrosis , 2001, Expert opinion on investigational drugs.
[109] C. Vandenberg,et al. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains , 2002, The EMBO journal.
[110] A. Goldberg,et al. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. , 1999, The Journal of nutrition.
[111] D J Glass,et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.
[112] John B. Thomas,et al. The Drosophila bendless gene encodes a neural protein related to ubiquitin-conjugating enzymes , 1993, Neuron.
[113] F. Grosveld,et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.
[114] J. Sutcliffe,et al. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons , 1997, Nature Genetics.
[115] O. Franco,et al. p27Kip1 is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells. , 2000, Anticancer research.
[116] W. Weiner,et al. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease , 2003, Current opinion in neurology.
[117] S. French,et al. The role of the ubiquitin-proteasome pathway in the formation of mallory bodies. , 2002, Experimental and molecular pathology.
[118] L. Staszewski,et al. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain , 1994, Cell.
[119] M. Figueiredo-Pereira,et al. Ubiquitin, cellular inclusions and their role in neurodegeneration , 1998, Trends in Neurosciences.
[120] T. Ohta,et al. The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.
[121] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[122] C. Fletcher,et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease , 2002, Nature Genetics.
[123] Harry T Orr,et al. Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in SCA1 Mice , 1999, Neuron.
[124] M. Karin,et al. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.
[125] Shinsei Minoshima,et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.
[126] Martin Scheffner,et al. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. , 2003, Seminars in cancer biology.
[127] S. Pulst,et al. Parkin is associated with actin filaments in neuronal and nonneural cells , 2000, Annals of neurology.
[128] F. R. Papa,et al. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene , 1993, Nature.
[129] A. Ferrús,et al. Ariadne-1: a vital Drosophila gene is required in development and defines a new conserved family of ring-finger proteins. , 2000, Genetics.
[130] Matthias Mann,et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.
[131] P. Elliott,et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. , 2000, Journal of autoimmunity.